| CD133 expression is not restricted to stem cells, and both CD133+ and CD133– metastatic colon cancer cells initiate tumors SV Shmelkov, JM Butler, AT Hooper, A Hormigo, J Kushner, T Milde, ... The Journal of clinical investigation 118 (6), 2111-2120, 2008 | 1159 | 2008 |
| Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive–like behaviors in mice SV Shmelkov, A Hormigo, D Jing, CC Proenca, KG Bath, T Milde, ... Nature medicine 16 (5), 598-602, 2010 | 372 | 2010 |
| Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia AH Shih, Y Jiang, C Meydan, K Shank, S Pandey, L Barreyro, ... Cancer cell 27 (4), 502-515, 2015 | 250 | 2015 |
| Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology SK Kumar, NS Callander, K Adekola, L Anderson, M Baljevic, ... Journal of the National Comprehensive Cancer Network 18 (12), 1685-1717, 2020 | 202 | 2020 |
| NCCN guidelines insights: Multiple myeloma, version 1.2020: Featured updates to the NCCN guidelines SK Kumar, NS Callander, J Hillengass, M Liedtke, M Baljevic, ... Journal of the National Comprehensive Cancer Network 17 (10), 1154-1165, 2019 | 157 | 2019 |
| NCCN Guidelines® insights: multiple myeloma, version 3.2022: featured updates to the NCCN guidelines NS Callander, M Baljevic, K Adekola, LD Anderson, E Campagnaro, ... Journal of the National Comprehensive Cancer Network 20 (1), 8-19, 2022 | 141 | 2022 |
| Angiomodulin is a specific marker of vasculature and regulates vascular endothelial growth factor-A–dependent neoangiogenesis AT Hooper, SV Shmelkov, S Gupta, T Milde, K Bambino, K Gillen, M Goetz, ... Circulation research 105 (2), 201-208, 2009 | 62 | 2009 |
| Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma C Gasparetto, S Lentzsch, G Schiller, N Callander, S Tuchman, C Chen, ... EJHaem 2 (1), 56-65, 2021 | 47 | 2021 |
| Selinexor, pomalidomide, and dexamethasone (SPd) in patients with relapsed or refractory multiple myeloma CI Chen, N Bahlis, C Gasparetto, SA Tuchman, BC Lipe, M Baljevic, ... Blood 134, 141, 2019 | 35 | 2019 |
| Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients C Gasparetto, GJ Schiller, SA Tuchman, NS Callander, M Baljevic, ... British journal of cancer 126 (5), 718-725, 2022 | 34 | 2022 |
| The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance JJ Castillo, NS Callander, M Baljevic, DW Sborov, S Kumar American journal of hematology 96 (7), 846-853, 2021 | 32 | 2021 |
| Recommendations on prevention of infections during chimeric antigen receptor T‐cell and bispecific antibody therapy in multiple myeloma M Mohan, R Chakraborty, S Bal, A Nellore, M Baljevic, A D'Souza, ... British Journal of Haematology 203 (5), 736-746, 2023 | 26 | 2023 |
| Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma M Baljevic, S Zaman, V Baladandayuthapani, YH Lin, CM de Partovi, ... Annals of hematology 96, 977-985, 2017 | 25 | 2017 |
| Telomere length recovery: a strong predictor of overall survival in acute promyelocytic leukemia M Baljevic, B Dumitriu, JW Lee, EM Paietta, PH Wiernik, J Racevskis, ... Acta haematologica 136 (4), 210-218, 2016 | 24 | 2016 |
| Epstein‐Barr Virus‐Related Hemophagocytic Lymphohistiocytosis: Hematologic Emergency in the Critical Care Setting N Hashemi-Sadraei, P Vejpongsa, M Baljevic, L Chen, M Idowu Case Reports in Hematology 2015 (1), 491567, 2015 | 24 | 2015 |
| Curing all patients with acute promyelocytic leukemia: are we there yet? M Baljevic, JH Park, E Stein, D Douer, JK Altman, MS Tallman Hematology/Oncology Clinics 25 (6), 1215-1233, 2011 | 23 | 2011 |
| Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology SK Kumar, NS Callander, K Adekola, LD Anderson, M Baljevic, R Baz, ... Journal of the National Comprehensive Cancer Network 21 (12), 1281-1301, 2023 | 22 | 2023 |
| Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM). D White, C Chen, M Baljevic, S Tuchman, NJ Bahlis, GJ Schiller, B Lipe, ... Journal of Clinical Oncology 39 (15_suppl), 8018-8018, 2021 | 22 | 2021 |
| Systemic light chain amyloidosis, version 2.2023, NCCN clinical practice guidelines in oncology SK Kumar, NS Callander, K Adekola, LD Anderson, M Baljevic, ... Journal of the National Comprehensive Cancer Network 21 (1), 67-81, 2023 | 18 | 2023 |
| Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM). C Gasparetto, B Lipe, S Tuchman, NS Callander, S Lentzsch, M Baljevic, ... Journal of Clinical Oncology 38 (15_suppl), 8530-8530, 2020 | 18 | 2020 |
